Enzyme – Talk Bio

Servier Pays $210M Upfront for Ex-US Rights to Ideaya’s PKC Inhibitor Darovasertib

1 week ago talkbio0Tagged Clinical Trials, Darovasertib, Ideaya Biosciences, Inhibitor, milestone payments, oncology licensing deal, Protein Kinase C, Protein Kinase C Inhibitor, royalties, Servier, uveal melanoma

Servier; Ideaya Biosciences; darovasertib; protein kinase C inhibitor; PKC inhibitor; uveal melanoma; oncology licensing deal; clinical trials; milestone payments; royalties

AbbVie’s Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

3 weeks ago talkbio0Tagged AbbVie, Alopecia, hair regrowth, Inhibitor, Janus kinase, Rinvoq, Salts, Score, upadacitinib

AbbVie; Rinvoq; Phase 3 trial; alopecia areata; hair regrowth; upadacitinib; SALT score; JAK inhibitor

Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

4 weeks ago talkbio0Tagged CDC7 protein, human, clinical trial halt, drug safety, Inhibitor, leukemia, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, patient deaths, Schrödinger, SGR-2921

Schrödinger; SGR-2921; leukaemia; acute myeloid leukaemia (AML); myelodysplastic syndromes (MDS); CDC7 inhibitor; clinical trial halt; patient deaths; drug safety

Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC

1 month ago talkbio0Tagged Accelerated, Approved, Beamion, Boehringer Ingelheim, competition, Confirmatory Trial, Enhertu, erbB-2 Receptor, Frequency of Responses, HER2-mutant, Hernexeos, Identifier, LUNG-1, Mutation, Non-Small Cell Lung Carcinoma, non-squamous NSCLC, Oncomine Dx Target Test, oral targeted therapy, Priority Review, Requirement, TKD, United States Food and Drug Administration, Zongertinib

Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

1 month ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

2 months ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

3 months ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations